Marshall Wace, LLP Regeneron Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

A detailed history of Marshall Wace, LLP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 134,004 shares of REGN stock, worth $104 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
134,004
Previous 58,873 127.62%
Holding current value
$104 Million
Previous $61.9 Million 127.66%
% of portfolio
0.18%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1024.09 - $1201.76 $76.9 Million - $90.3 Million
75,131 Added 127.62%
134,004 $141 Million
Q2 2024

Aug 14, 2024
SELL
$883.2 - $1071.19 $125 Million - $152 Million
-141,514 Reduced 70.62%
58,873 $61.9 Million
Q1 2024

May 15, 2024
BUY
$902.69 - $993.35 $95.6 Million - $105 Million
105,861 Added 111.99%
200,387 $193 Million
Q4 2023

Feb 14, 2024
SELL
$775.18 - $881.7 $8.33 Million - $9.48 Million
-10,751 Reduced 10.21%
94,526 $83 Million
Q3 2023

Nov 14, 2023
SELL
$692.45 - $844.37 $26.5 Million - $32.3 Million
-38,231 Reduced 26.64%
105,277 $86.6 Million
Q2 2023

Aug 14, 2023
BUY
$700.03 - $830.35 $36.9 Million - $43.8 Million
52,710 Added 58.05%
143,508 $103 Million
Q1 2023

May 15, 2023
BUY
$680.49 - $826.97 $55.2 Million - $67.1 Million
81,098 Added 836.06%
90,798 $74.6 Million
Q4 2022

Feb 14, 2023
BUY
$705.89 - $766.39 $3.95 Million - $4.29 Million
5,595 Added 136.3%
9,700 $7 Million
Q3 2022

Nov 14, 2022
SELL
$573.97 - $724.32 $27.5 Million - $34.7 Million
-47,950 Reduced 92.11%
4,105 $2.83 Million
Q2 2022

Aug 15, 2022
BUY
$548.35 - $738.84 $26.4 Million - $35.6 Million
48,188 Added 1246.13%
52,055 $30.8 Million
Q1 2022

May 16, 2022
SELL
$595.12 - $698.43 $74.5 Million - $87.4 Million
-125,161 Reduced 97.0%
3,867 $2.7 Million
Q4 2021

Feb 14, 2022
BUY
$543.48 - $670.97 $13.6 Million - $16.8 Million
25,056 Added 24.1%
129,028 $81.5 Million
Q3 2021

Nov 15, 2021
BUY
$574.03 - $680.96 $18.1 Million - $21.5 Million
31,520 Added 43.5%
103,972 $62.9 Million
Q2 2021

Aug 13, 2021
BUY
$472.8 - $558.54 $25.7 Million - $30.4 Million
54,384 Added 301.0%
72,452 $40.5 Million
Q1 2021

May 17, 2021
BUY
$446.73 - $548.2 $6.9 Million - $8.47 Million
15,448 Added 589.62%
18,068 $8.55 Million
Q4 2020

Feb 16, 2021
BUY
$478.3 - $607.98 $1.25 Million - $1.59 Million
2,620 New
2,620 $1.27 Million
Q3 2020

Nov 16, 2020
SELL
$544.75 - $658.21 $7.23 Million - $8.73 Million
-13,270 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$493.32 - $643.92 $6.55 Million - $8.54 Million
13,270 New
13,270 $8.28 Million
Q1 2020

May 15, 2020
SELL
$336.18 - $494.43 $8.83 Million - $13 Million
-26,276 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$274.13 - $376.51 $4.79 Million - $6.57 Million
17,461 Added 198.08%
26,276 $9.87 Million
Q3 2019

Nov 14, 2019
SELL
$273.46 - $318.39 $30.7 Million - $35.8 Million
-112,360 Reduced 92.73%
8,815 $2.45 Million
Q2 2019

Aug 14, 2019
BUY
$299.6 - $414.82 $36.3 Million - $50.3 Million
121,175 New
121,175 $37.9 Million
Q1 2019

May 14, 2019
SELL
$372.08 - $439.57 $484,820 - $572,759
-1,303 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$335.82 - $403.04 $437,573 - $525,161
1,303 New
1,303 $487,000
Q3 2018

Nov 14, 2018
SELL
$351.14 - $408.51 $3.06 Million - $3.56 Million
-8,703 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$284.6 - $344.99 $2.48 Million - $3 Million
8,703 New
8,703 $3 Million

Others Institutions Holding REGN

# of Institutions
1,534
Shares Held
83.8M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $83.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email